

ASX/Media Release

0709/2020

Issue of Placement Shares

Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence company that develops remote patient monitoring technology underpinned by a clinical services model to evaluate the safety and effectiveness of new treatments, is pleased to advise that it has today issued 27,500,000 shares at an issue price of \$0.08 raising \$2.2 million (before costs) (**Placement**)

Funds raised in the Placement, which received strong demand from a combination of new and existing institutional and sophisticated investors in Australia and international markets, will be used for expansion of clinical services, research and development, business development opportunities and general working capital .

The new shares have been issued utilising the Company's existing placement capacity under ASX Listing Rule 7.1.

An Appendix 2A applying for quotation of the shares issued under the Placement, together with a cleansing notice in respect of those shares under section 708A(5)(e) of the Corporations Act 2001 (Cth), will follow this announcement.

Release authorised by: Dr Michael Winlo, CEO and Managing Director

For further information:

Dr Michael Winlo
CEO
(08) 6559 2800
investors@emeraldclinics.com.au

Matt Wright
Media/investor relations
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Emerald Clinics Limited

Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company focussed on generating Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology. The Emerald model provides care while also co-creating high quality and ethically sourced clinical data from informed and consenting patients. Emerald's evidence is used to accelerate the development of new treatments and models of care. Emerald customers pay for deidentified data, clinical trials and consulting services or monitor their workforce.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the



Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.